<DOC>
	<DOCNO>NCT00904410</DOCNO>
	<brief_summary>18F-FDG PET , whole-body image technology base glucose metabolism , effectively detect subclinical clinical therapeutic response stage earlier detect conventional approach . We propose conduct prospective study evaluate early therapeutic response use 18F-FDG PET 1st cycle neo-adjuvant chemotherapy breast cancer patient . Variation 18F-FDG PET uptake compare clinical echographical tumor response evaluate 3 cycle chemotherapy . The purpose estimate capacity 18F-FDG PET differentiate responder non-responder patient .</brief_summary>
	<brief_title>Early Assessment Response Neo-adjuvant Chemotherapy Breast Cancer Patients With FDG-PET</brief_title>
	<detailed_description>Further study detail provide Centre Oscar Lambret</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age &gt; 18 Breast cancer treat neoadjuvant chemotherapy ( T &gt; 2cm ) Measurable lesion , assess clinically ultrasound Delay minimum biopsy PET : 15 day PSWHO : 0 T &lt; 2cm Inflammatory breast cancer ( T4d ) Diabetic patient unbalanced ( glycemia &gt; 1.40 ) Pregnant lactate woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>breast</keyword>
</DOC>